Bristol Myers Squibb Co. has prepared and tested new Substituted benzimidazole compounds acting as Toll-like receptor 9 (TLR9) antagonists. They are reported to be useful for the treatment of fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, cancer, primary sclerosing cholangitis, idiopathic pulmonary fibrosis, inflammatory and autoimmune diseases.

Synnovation Therapeutics Inc. has patented phosphatidylinositol 3-kinase α (PI3K-α) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities).

Hemoshear Therapeutics Inc. has identified new 3-((1,1-dioxido-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)-2-fluoroacrylic acid derivatives acting as sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors.

Nanjing Medical University and the Shanghai Institutes of Materia Medica and Nutrition & Health of the Chinese Academy of Sciences have prepared and tested 1,2,3,4-tetrahydropyridone compounds acting as Jumonji domain-containing protein 1C (JMJD1C; TRIP-8) inhibitors. As such, they are described as potentially useful for the treatment of cancer.

A patent from Centre National de la Recherche Scientifique (CNRS), McGill University and Sorbonne University discloses new acetylcholinesterase (AChE) inhibitors reported to be useful for the treatment of substance abuse and dependence, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, obesity, Parkinson’s and Alzheimer’s disease.

Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the discovery of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Daegu-Gyeongbuk Medical Innovation Foundation and Provibio Co. Ltd. have identified new compounds described as potentially useful for the treatment of cancer and autoimmune diseases.

Cincinnati Children’s Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have jointly patented interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.

The Institute of Physical and Chemical Research, the National Institute of Infectious Diseases Japan and Shizuoka Prefectural University have discovered prodrugs of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors and reported to be useful for the treatment of viral infection.

Copper complexes acting angiogenesis inhibitors have been disclosed in a patent from Istinye Universitesi and Karadeniz Teknik Universitesi Teknoloji Transferi Uygulama ve Arastirma Merkezi as potentially useful for the treatment of cancer.